CLINICAL ROLE -
New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab
Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Read More
Use of Long-Acting Injectable Antipsychotic Medications in Schizophrenia Treatment
Personalized Prevention: Identifying At-Risk Patients With Image-Based Screening
APhA 2025: Empowering Pharmacy Leaders With Mindful Self-Care Strategies
Expert Q&A: Role of Pharmacists in COVID-19 Care, Prevention Continues to Evolve